SwanBio Therapeutics is a gene therapy company focused on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders

The company, which is located in Boston and Philadelphia, is building on its proprietary delivery and manufacturing know-how to enable it to deliver its products commercially, which it will leverage for each of its pipeline products.

The business is based on work by Florian Eichler, a founder of SwanBio and Associate Professor of Neurology at Harvard Medical School and Assistant in Neurology, Director of the Leukodystrophy Clinic, and Director of the Center for Rare Neurological Diseases at Massachusetts General Hospital. Its lead programme is in development for a monogenic neurodegenerative condition impacting approximately one in 17,000 people.

Developing

Company Details

Syncona Representatives:

Chris Hollowood
Alex Hamilton

Latest updates

There are currently no updates for SwanBio.